Epigenetic repression of miR-17 contributed to di(2-ethylhexyl) phthalate-triggered insulin resistance by targeting Keap1-Nrf2/miR-200a axis in skeletal muscle

Jie Wei1#, Qiongyu Hao3#, Chengkun Chen1, Juan Li1, Xikui Han1, Zhao Lei2, Tao Wang4, Yinan Wang1, Xiang You1, Xiaoxuan Chen2, Huasheng Li1, Yuxin Ding1, Weihao Huang1, Yangyang Hu1, Shuirong Lin1, Heqing Shen2# and Yi Lin2#

1. Department of Basic Medical Sciences, School of Medicine, Xiamen University, Xiamen 361102, China.
2. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen 361102, China.
3. Division of Cancer Research and Training, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, David Geffen UCLA School of Medicine, and UCLA Jonsson Comprehensive Cancer Center, 1748 E. 118th Street, Los Angeles, CA, 90059, USA.
4. The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China.

#These authors contributed equally to this work.

Abstract

Rationale: Skeletal muscle insulin resistance is detectable before type 2 diabetes is diagnosed. Exposure to di(2-ethylhexyl) phthalate (DEHP), a typical environmental endocrine-disrupting chemical, is a novel risk factor for insulin resistance and type 2 diabetes. This study aimed to explore insulin signaling regulatory pathway in skeletal muscle of the DEHP-induced insulin-resistant mice and to investigate potential therapeutic strategies for treating insulin resistance.

Methods: C57BL/6j male mice were exposed to 2 mg/kg/day DEHP for 15 weeks. Whole-body glucose homeostasis, oxidative stress and deregulated miRNA-mediated molecular transduction in skeletal muscle were examined. microRNA (miRNA) interventions based on lentiviruses and adeno-associated viruses 9 (AAV9) were performed.

Results: Dnmt3a-dependent promoter methylation and lncRNA Malat1-related sponge functions cooperatively downregulated miR-17 in DEHP-exposed skeletal muscle cells. DEHP suppressed miR-17 to disrupt the Keap1-Nrf2 redox system and to activate oxidative stress-responsive Txnip in skeletal muscle. Oxidative stress upregulated miR-200a, which directly targets the 3'UTR of Insr and Irs1, leading to hindered insulin signaling and impaired insulin-dependent glucose uptake in skeletal muscle, ultimately promoting the development of insulin resistance. AAV9-induced overexpression of miR-17 and lentivirus-mediated silencing of miR-200a in skeletal muscle ameliorated whole-body insulin resistance in DEHP-exposed mice.

Conclusions: The miR-17/Keap1-Nrf2/miR-200a axis contributed to DEHP-induced insulin resistance. miR-17 is a positive regulator, whereas miR-200a is a negative regulator of insulin signaling in skeletal muscle, and both miRNAs have the potential to become therapeutic targets for preventing and treating insulin resistance or type 2 diabetes.

Key words: Environmental endocrine-disrupting chemical, Insulin resistance, microRNA, Oxidative stress, Skeletal muscle
Introduction

Type 2 diabetes (T2D) is a chronic disease characterized by hyperglycemia resulting from peripheral insulin resistance (IR) and pancreatic β cells failure. During the last decade, exposure to environmental endocrine-disrupting chemicals (EDCs) has been implicated as a novel contributor to the epidemic of T2D [1, 2]. Di(2-ethylhexyl) phthalate (DEHP) is one of the most common EDCs used in consumer, medical, and construction products. Several cross-sectional analyses consistently showed that urinary concentrations of DEHP and its metabolites were associated with increased IR or T2D in US adolescents [3, 4], as well as adult men [5] and women [6]. Another study focusing on the Canadian population, including males and females, and young and old individuals, also noted that exposure to DEHP might contribute to prediabetes [2]. Consistent with epidemiological studies, the role of DEHP in glucometabolic disorders was shown in our previous studies in vivo and in vitro [7, 8], and further investigation is needed to elucidate the mechanism by which DEHP acts to induce this risk.

Skeletal muscle IR (SkM-IR) is an early event and primary deficiency in the process of T2D [9-11]. Gestational exposure to DEHP predisposed offspring to glucometabolic dysfunction in adulthood by downregulating insulin signaling genes, including Insr, Irs1, and Akt, and inducing epigenetic alteration of Glut4 in the gastrocnemius muscle of rats [12]. The direct effects of DEHP on insulin signal transduction and Glut4 translocation were also confirmed in rat L6 myotubes [13]. Interestingly, the antioxidants vitamins C and E alleviated DEHP-induced SkM-IR in rats [14]. The role of oxidative stress in DEHP-induced IR was also emphasized in a cross-sectional pilot study in which exposure to DEHP at the community level promoted IR in 10-13-year-old children by inducing systemic oxidant stress, characterized by the increased urinary level of F2-isoprostane [15]. Nrf2 is a master regulator of the cytoprotective program against oxidative stress and, more importantly, has the capability to detoxify DEHP [16, 17]. Our previous study indicated a critical role for the Nrf2-mediated antioxidant response in DEHP-induced rat insulinoma INS-1 cells dysfunction [8]. Whether DEHP-induced IR was also related to an impairment of the Nrf2 redox system in SkM is worthy of further study.

microRNAs (miRNAs) act as epigenetic regulators by posttranscriptionally repressing target mRNAs. We previously showed that miR-200a/141 acted to target Keap1 directly and then regulated Nrf2 under high-glucose conditions, resulting in diabetic nephropathy in mice [18]. The function of the miR-200 family in regulating oxidative stress [19-21] and glucose homeostasis [22-25] has been demonstrated. In addition to miR-200a, our previous studies suggested the role of specific miRNA (including miR-338, miR-192 and miR-26a) modifications in regulating environmental cues such as bisphenol A and ambient particulate matter-induced disorders of glucose and lipid metabolism [26-29]. To date, few studies regarding the influence of miRNA deregulation on DEHP-associated injury have been published. Therefore, this study intended to examine the mechanism by which the mutual functional status of the keap1-Nrf2 pathway and miRNAs, including miR-200a, contributed to DEHP-induced SkM-IR and, more importantly, to investigate potential targets to intervene in IR.

Methods

Animal Experiments

All animal experiments were carried out in accordance with the guidelines of the Xiamen University Institutional Committee for the Care and Use of Laboratory Animals (XMULAC20150081).

Three-week-old male healthy C57BL/6 mice were purchased from the SLAC Laboratory Animal Center (Shanghai, China) and housed (5 mice/cage) under specific pathogen-free conditions (Xiamen University Laboratory Animal Center, Xiamen, China) with controlled room temperature (22 ± 2 °C), humidity (55 ± 5%) and a 12:12 h light-dark cycle. Mice had ad libitum access to food and water. The diet (standard rodent chow diet, Xietong Organism Institute, Nanjing, China) contained 12% fat, 20.6% protein and 67.4% carbohydrates, with energy of 3.616 kJ/g. After 1 week of adaption, the mice were administered corn oil (Sigma-Aldrich, MO, USA) or 2 mg/kg/day of DEHP (J&K Chemical, Shanghai, China) dissolved in corn oil (Millipore-Sigma, MO, USA) by oral gavage. After 15 weeks of DEHP administration, the C57BL/6 mice were anaesthetized and sacrificed by decollation.

For antioxidant treatment, 2 mM N-acetyl-cysteine (NAC, Millipore-Sigma) was administered to DEHP-exposed mice in drinking water throughout the experimental period. For miR-200a inhibition, DEHP-exposed mice were administered anti-miR-200a lentivirus (SBO Medical Biotechnology, Shanghai, China) through intramuscular injections on the 1st, 5th, 10th, 15th and 20th day for a total of five injections at a concentration of 1×10^7 transducing units each time. For miR-17 overexpression in SkM, DEHP-exposed mice received adenovirus-associated virus 9 (AAV9)-delivered miR-17 (SBO Medical Biotech-
nology) at a titer of $5 \times 10^9$ particles via intramuscular injections. The AAV9 vectors were delivered 4 weeks prior to SkM tissue collection.

**Cell culture and treatment**

Mouse C2C12 myoblast cells (Shanghai Institute of Cell Biology, Chinese Academy of Sciences) were cultured in DMEM (Thermo Fisher Scientific, MA, USA) supplemented with 10% FBS (Thermo Fisher Scientific). When the C2C12 myoblasts reached 80% confluence, the cells were switched to differentiation medium consisting of DMEM supplemented with 2% horse serum (Thermo Fisher Scientific). Myotubes were used for experiments after 6 days of differentiation (Figure S3). Differentiated C2C12 myotubes were treated with serial concentrations (0, 1, 5, and 25 $\mu$M) of DEHP for 48 h.

For inhibition and overexpression of miR-200a and miR-17, C2C12 myotubes were transfected with 50 nM agomiR-200a or agomiR-17 (Ribobio, Guangzhou, China), 200 nM antagoniR-200a or antagoniR-17, and their corresponding controls for 48 h. To inhibit Txnip and Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (lncRNA Malat1), C2C12 myotubes were transfected with the corresponding siRNAs at a final concentration of 100 nM (Santa Cruz Biotechnology, CA, USA). For Nrf2 activation, C2C12 myotubes were pretreated with the chemical Nrf2 inducer sulforaphane (SFN, 5 $\mu$M, Millipore-Sigma) before 2′-deoxycytidine (5-aza, 10 $\mu$M, Millipore-Sigma) was applied to DEHP-exposed cells for 15 min before harvesting.

**Luciferase reporter assays**

Wild-type and mutated mouse *Insr*, *Irs1* and *Keap1* 3′UTR sequences were PCR-amplified from cDNA using specific primers (Table S1). The wild-type (WT) or mutant (MT) 3′UTRs were cloned into the pmiR-RB-REPORT vector (Ribobio). For luciferase reporter assays, C2C12 myotubes were cotransfected with the indicated 3′UTR luciferase reporter vectors and agomiR-200a, antagoniR-200a, agomiR-17, or antagoniR-17 for 48 h. The relative luciferase activities were measured using a dual-luciferase reporter assay kit (Promega, WI, USA).

**Metabolic measurements**

For the glucose tolerance test (GTT), overnight-fasted mice were injected intraperitoneally with glucose at a dose of 2.0 g/kg. For the insulin tolerance test (ITT), 6-h-fasted mice were injected intraperitoneally with 0.75 U/kg insulin (Novolin R; Novo Nordisk A/S, Bagsvaerd, Denmark). Glucose values were converted into natural logarithm (Ln) and the slope of the decline in the blood glucose concentration from 0 to 30 min was calculated using linear regression ([time $\times$ Ln (glucose)]) and multiplied by 100 to obtain the constant rate for glucose disappearance (KITT) [30, 31]. Blood samples were collected at regular intervals (0-120 min). Blood glucose was measured by a handheld glucose meter (Accu-Chek Active; Roche, Mannheim, Germany). Serum insulin was analyzed with ELISA kits (Alpco Diagnostics, NH, USA). For insulin signaling experiments, mice were fasted overnight and intraperitoneally injected with 1 U/kg insulin solution (Novolin R). After 10 min, the mice were sacrificed and gastrocnemius SkM were harvested. For the *in vitro* cultured model, the treated C2C12 myotubes were stimulated with 100 nM insulin (ProSpec-Tany Technogene, Ness Ziona, Israel) for 15 min before harvesting.

**Glucose uptake assay**

2-Deoxyglucose (2-DG) uptake was assessed using a glucose uptake kit (ab136955, Abcam, Cambridge, UK). Briefly, C2C12 myotubes were starved in serum-free medium overnight and incubated for 40 min at 37 °C in the absence or presence of 100 nM insulin in Krebs-Ringer-phosphate-HEPES (KRPH) buffer with 2% bovine serum albumin (BSA). Glucose transport was analyzed following the addition of 10 μL of 10 mM 2-DG to insulin-stimulated cells and to noninsulin-stimulated control cells for 20 min. 2-DG is metabolized by cells into 2-DG-phosphate (2-DG6P), which results in the oxidation of a substrate. The oxidized substrate was detected at OD412 nm. Data were corrected for protein content, and the protein concentrations of the protein lysates were measured by a Pierce™ BCA Protein Assay kit (Thermo Fisher Scientific).

**Oxidative stress detection**

Gastrocnemius SkM and C2C12 myotubes were homogenized in ice-cold lysis buffer. The levels of reduced glutathione (GSH) and oxidized glutathione (GSSG) in the lysates and serum were measured using glutathione assay kits (Meimian, Yancheng, China). The content of H$_2$O$_2$ in lysates and serum were measured using an enzyme-linked immunosorbent assay kit (Meimian).

**Immunohistochemistry analysis**

Freshly harvested gastrocnemius SkM was fixed in 4% paraformaldehyde and embedded in paraffin, and sectioned into 5-μm-thick sections onto poly-l-
lysine-coated glass slides. The sections were incubated overnight with primary antibodies against Tnixip (Proteintech Group, IL, USA, 18243-1-AP, 1:100), Keap1 (sc-514914, 1:100), and Nrf2 (16396-1-AP, 1:200). Immunostaining was visualized with 3,3-diaminobenzidine substrate.

**Immunofluorescence staining**

The sections were incubated with primary antibodies against Irs1 (sc-559, 1:100) overnight at 4 °C. Thereafter, the sections were incubated with Cy3-conjugated goat anti-rabbit secondary antibodies (Wuhan Boster Company, Wuhan, China, 1:100) for 1 h, followed by a 5-min incubation with DAPI (Beyotime Biotechnology, Haimeng, China). Conventional epifluorescence microscopy was used to capture for images (Leica DM2700 P, Germany).

**Transmission electron microscope (TEM)**

Gastrocnemius SkM was cut into small pieces, fixed in 2.5% glutaraldehyde for 2 h at 4 °C, and postfixed in 1% osmium tetroxide for 1 h at 4 °C. The tissue was further dehydrated with graded alcohol, embedded in resin, and cut using an ultramicrotome (Leica, German). The ultrathin sections (60-80 nm) were mounted on copper grids, stained with uranyl acetate and lead citrate, and then observed with a transmission electron microscope (HT-7800, Hitachi, Japan). The size of mitochondria was measured using ImageJ software (National Institutes of Health, DC, USA).

**mRNA and miRNA expression**

Total RNA, including miRNA, was extracted using TRIZol (Thermo Fisher Scientific), and real-time PCR was carried out by SYBR Green Real-Time PCR Master Mix (Toyobo, Osaka, Japan) on a StepOne Real-Time Quantitative PCR system (Thermo Fisher Scientific). The primers were listed in Tables S2 and S3.

**Western blot analysis**

Total protein was prepared using RIPA (Thermo Fisher Scientific). The plasma membrane protein was prepared using a membrane protein extraction kit (Thermo Fisher Scientific) and the tissue nuclear protein was prepared using NE-PER nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific). The protein was separated by electrophoresis on SDS-polyacrylamide gels and immunoblotted with antibodies against pAkt(F473) (Cell Signaling Technology, MA, USA, #4060, 1:500), Akt (CST, #9227, 1:2000), Glut4 (sc-53566, 1:500), Insr (CST, #3025, 1:1000), pInsrTyr115/115 (CST, #3024, 1:500), Irs1 (sc-515017, 1:500), pIrs1Tyr608 (Merck Millipore, 09-432, 1:1000), Tnixip (CST, #14715, 1:1000), Keap1 (CST, #8047, 1:1000), Nrf2 (Abcam, ab137550, 1:2000), Dnmt3a (CST, #3598, 1:1000), Lamin B1 (CST, #13435, 1:1000) and Gapdh (CST, #2118, 1:2000). The antibody-reactive bands were visualized using ECL chemiluminescence detection system (Western-Bright™ ECL Western Blotting HRP Substrate, Advansta, CA, USA) and the band intensity was quantified by Image J software (National Institutes of Health).

**Statistical analysis**

All data were presented as the mean ± SEM. Comparisons between two groups were performed by two-tailed Student’s t test. Multiple comparisons were performed using one-way ANOVA followed by the Bonferroni post hoc test. Statistical analyses were performed using GraphPad Prism 7. The data were considered significant when P < 0.05 or P < 0.01.

**Results**

**Exposure to DEHP induced IR**

As shown in Figure 1A, there was no difference in body weight during the 15-wk exposure period. The fasted blood glucose was increased in DEHP-exposed mice (Figure 1B), whereas no difference was shown in fasting serum insulin (Figure 1C). GTT showed prolonged elevation of blood glucose at 30 and 60 min (Figure 1D) and higher glucose AUC (Figure S1C) in DEHP-exposed mice. When challenged with ITT, the decrease in blood glucose was less pronounced in DEHP-exposed mice at 30 and 60 min after administration of insulin than in control mice (Figure 1E). Moreover, lower glucose decay constant rate (KITT) during the ITT was shown in DEHP-exposed mice (Figure 1F), indicating a decreased systemic insulin sensitivity. In addition, the homeostasis model assessment of IR (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI) were further calculated and the results consistently showed that HOMA-IR was higher, whereas the QUICKI was lower in mice exposed to DEHP compared with control mice (Figure S1A-B), indicative of whole-body IR. In SkM, DEHP decreased the expression and phosphorylation of Insr and Irs1 (Figure 1G-J). And in response to insulin stimulation, decreased phosphorylation of Akt at Ser473 and defective Glut4 trafficking were also shown in SkM of DEHP-exposed mice (Figure 1K-M). Additionally, mitochondria in SkM of DEHP-exposed mice were structurally swollen, enlarged and rounded with disorganized cristae and vacuolar structure (Figure 1N). The mRNA and protein expression of Keap1 was increased whereas both total and nuclear protein level of Nrf2 were decreased in SkM of DEHP-exposed mice (Figure 1O and Figure 2A-B). The dysregulated
Keap1-Nrf2 system was abrogated by NAC administration (Figure 2A-B), implying a link between oxidative stress and SkM-IR.
Figure 2. NAC Prevented DEHP-induced IR. A-B. The representative western blot images and quantification of oxidative stress-related genes (n = 3 mice per group). The total protein was normalized by Gapdh and the protein expression of Nrf2 in nuclear were normalized by Lamin B1. C. The calculated GSH/GSSG ratio in serum (n = 5 mice per group). The serum levels of reduced glutathione (GSH) and oxidized glutathione (GSSG) were shown in Figure S2C-D. D. The serum level of H2O2 (n = 5 mice per group). E. The calculated GSH/GSSG ratio in SkM (n = 5 mice per group). The levels of GSH and GSSG in SkM were shown in Figure S2E-F. F. The content of H2O2 normalized to protein content in SkM (n = 5 mice per group). G. The fasting blood glucose (n = 10 mice per group). H. The IPGTT (n = 5 mice per group). The AUC of the IPGTT were shown in Figure S2G. I. ITT (n = 5 mice per group). J. The KITT obtained in ITT (0-30min). K-L. The representative western blot images (K) and quantification (L) of insulin-stimulated pAkt and the Glut4 translocation in SkM (n = 3 mice per group). The basal levels (without insulin stimulation) of pAkt and mGlut4 was shown in Figure S2H. M-N. The expression and phosphorylation of Insr and Irs1 in SkM. Quantitative results were normalized by Gapdh (n = 3 mice per group). O. The expression of mir-200 family in SkM of mice (n = 4 mice per group). U6 was used to normalized miRNA expression. P. The putative sequence interactions between mir-200a (mir-141) and 3'UTR of Insr and Irs1, respectively. Mmu, mouse; Hsa, human. All data were presented as the mean ± SEM. *P < 0.05 control mice vs. DEHP-exposed mice, **P < 0.01 control mice vs. DEHP-exposed mice. ***P < 0.05 DEHP-exposed mice vs. DEHP-exposed mice co-treated with NAC. ****P < 0.01 DEHP-exposed mice vs. DEHP-exposed mice co-treated with NAC.
**Oxidative stress acted as an insulin desensitizer in SkM and contributed to DEHP-induced IR**

Exposure to DEHP reduced GSH/GSSG ratio and increased H2O2 in both serum (Figure 2C,D) and SkM (Figure 2E,F). These changes were accompanied by upregulation of Txnip (Figure 2A,B). NAC administration reversed the increased H2O2 production, reduced GSH/GSSG ratio, impaired Keap1-Nrf2 pathway and increased Txnip in SkM of DEHP-exposed mice (Figure 2A, B, E and F). In parallel with protection against oxidative stress, NAC restored hyperglycemia and improved glucose tolerance and insulin sensitivity in DEHP-exposed mice (Figure 2G-J). No difference in body weight and serum insulin was observed among control, DEHP-exposed and DEHP and NAC co-treated mice (Figure S2A-B). The decreases in Insr, Irs1 and insulin-stimulated plnsr, plrs1, pAkt and mGlut4 in SkM of DEHP-exposed mice was reversed after cotreatment with the NAC (Figure 2K-N).

**miR-200a suppressed insulin signaling in SkM cells by targeting the 3′UTR of Insr and Irs1**

The expression of the miR-200 family was examined, and Figure 2O showed that miR-200a and miR-141 were increased in SkM of DEHP-exposed mice compared with that of control mice, while NAC inhibited this upregulation. miR-200a and miR-141 have homologous seed regions (Figure 2P), and hence, should exhibit similar regulatory modes and have the potential to regulate the expression of same target genes. This study mainly focused on miR-200a. Figure 3A-E showed that overexpression of miR-200a in C2C12 myotubes decreased insulin-stimulated pAkt, mGlut4 and glucose uptake. Moreover, overexpression of miR-200a decreased Insr and Irs1, and vice versa (Figure 3F-J). Computational algorithms predicted that the 3′UTR of both Insr and Irs1 contained sequences matching the seed sequences for miR-200a (Figure 2P). And Figure 3K and M further indicated that overexpression of miR-200a in C2C12 myoblasts decreased luciferase activity of the reporter gene fused with truncated Insr- or Irs1-3′-UTR sequences containing predicted miR-200a binding site, whereas inhibition of miR-200a had the opposite effects. Both the inhibitory effects of agomiR-200a and the inducible effects of antagonim-200a were abolished when the putative 3′UTR-binding sites were disrupted (Figure 3L and N). In addition, Figure 3O-Q further showed that miR-200a overexpression failed to inhibit insulin-stimulated pAkt and mGlut4 when Irs1 was overexpressed by pEGFP-N1-Irs1, reinforcing the idea that miR-200a suppressed insulin signaling in SkM cells by targeting Irs1.

**Inhibition of miR-200a improved DEHP-induced IR**

Consistent with the in vivo data, the expression of miR-200a was increased, but Insr and Irs1 were decreased in C2C12 myotubes exposed to serial concentrations of DEHP (Figure 4A-C). No obvious evidence of relationship between the dose of DEHP and the miR-200a, Insr or Irs1 expression was observed. Treatment of C2C12 myotubes with DEHP also led to a decrease in GSH (Figure 4D), insulin-stimulated pAkt (Figure 4E,F) and glucose uptake (Figure 4G,H). Both the downregulation of Insr and Irs1 and the inhibition of glucose uptake was prevented in the presence of antagonim-200a (Figure 4I-K). In vivo, inhibition of miR-200a via LV-miR-200a injection (Figure 5A) did not alter body weight (Figure 5B), serum H2O2 (Figure 5C) and fasting blood glucose (Figure 5A) in DEHP-exposed mice, but fasting serum insulin (Figure 5D) was decreased when DEHP-exposed mice received LV-miR-200a. Meanwhile, the GTT and ITT showed that restoration of SkM miR-200a expression improve glucose tolerance and insulin sensitivity in DEHP-exposed mice (Figure 5E-G). miR-200a inhibition also abrogated the DEHP-induced downregulation of Insr and Irs1 (Figure 5H-J), which was accompanied by plnsr, plrs1, pAkt and mGlut4 normalization in response to insulin (Figure 5H, I and K).

**Impaired Keap1-Nrf2 system and activated Txnip contributed to miR-200a upregulation in DEHP-exposed SkM cells under oxidative stress**

Although both NAC and anti-miR-200a lentivirus administration reversed IR in DEHP-exposed mice, the H2O2 content (Figure 5L) and the mRNA expression of Keap1 and Nrf2 (Figure 5M) were not changed in SkM of DEHP-exposed mice after anti-miR-200a lentivirus injection. In C2C12 myotubes, DEHP increased the expression of Txnip (Figure S6A), while the loss of Txnip decreased miR-200a and enhanced insulin-stimulated glucose uptake in DEHP-exposed myotubes (Figure S6B-D). In addition, increased keap1 and decreased Nrf2 were observed in DEHP-treated C2C12 myotubes (Figure S7A,B). The Nrf2 activator SFN elevated GSH content and reversed DEHP-induced upregulation of miR-200a and Txnip in C2C12 myotubes, thereby restoring the defective ability of insulin-stimulated glucose uptake (Figure S7C-G).
Figure 3. Upregulation of miR-200a impaired insulin sensitivity by targeting Insr and Irs1 in SkM cells. C2C12 myotubes were transfected with 50 nM agomiR-200a or 200 nM antagomir-200a for 48 h. A. The expression of miR-200a normalized by U6 (n = 4 independent experiments). B-D. The insulin-stimulated pAkt and the Glut4 translocation in miR-200a-overexpressing and miR-200a-inhibiting C2C12 myotubes (n = 3 independent experiments). Gapdh was used as the loading control. E. The 2-deoxyglucose (2-DG) uptake in miR-200a-overexpressing and miR-200a-inhibiting C2C12 myotubes (n = 3 independent experiments). F-J. The protein (F-H) and mRNA (I-J) expression of Insr and Irs1. Gapdh was used as the loading control (n = 3 independent experiments). K and M. The relative luciferase activity in C2C12 myoblasts transfected with reporter vector containing the wild Insr (H) or Irs1 (J) 3’UTR together with agomiR-200a, antagomiR-200a or corresponding control (n = 4 independent experiments). The location of the miR-200a binding sites were shown in Figure 2P. L and N. The relative luciferase activity in the C2C12 myoblasts transfected with reporter vector containing the mutant Insr (I) or Irs1 (K) 3’UTR together with agomiR-200a, antagomiR-200a or corresponding control (n = 4 independent experiments). Mutated miR-26a binding site was shown in Table S1. O-Q. The insulin stimulated Akt phosphorylation and Glut4 translocation in C2C12 myotubes cotransfected with agomiR-200a and transfected with pEGFP-N1-Irs1 plasmid (n = 3 independent experiments). Gapdh was used as the loading control. All data were presented as the mean ± SEM. *P < 0.05, **P < 0.01 vs. corresponding control as indicated.
Figure 4. The role of DEHP exposure in C2C12 myotubes. A-G. C2C12 myotubes were treated with serial concentrations of DEHP for 48 h (n = 3 independent experiments). A. The expression of miR-200a normalized by U6. B-C. The mRNA expression of Insr (B) and Irs1 (C) normalized by Gapdh. D. The content of GSH normalized to protein content in DEHP-exposed C2C12 myotubes. Gapdh was used as the loading control. E-F. The representative western blot images (E) and quantification (F) of pAkt in DEHP-exposed C2C12 myotubes. Gapdh was used as the loading control. G-H. The basal (G) and insulin-stimulated (H) 2-DG uptake in DEHP-exposed C2C12 myotubes transfected with 200 nM antagomir-200a and treated with 25 µM DEHP (n = 3 independent experiments). Gapdh was used as the loading control. K. The insulin-stimulated 2-DG uptake in C2C12 myotubes transfected with 200 nM antagomir-200a and treated with 25 µM DEHP (n = 3 independent experiments). All data were presented as the mean ± SEM. *P < 0.05, **P < 0.01 vs. corresponding control as indicated.

Downregulation of miR-17 impaired glucose uptake by inducing oxidative stress via directly targeting keap1

In addition to changes in miR-141 and miR-200a, exposure to DEHP decreased the expression of miR-17 both in vitro and in vivo (Figure S8A and Figure 7A). Inhibition of miR-17 upregulated Keap1 and Txnip, and downregulated Nrf2 in C2C12 myotubes; whereas overexpression of miR-17 produced the opposite effect (Figure 6A-D and Figure S8B). Moreover, the 3’UTR of Keap1 contained a binding site complementary to miR-17 (Figure 6E), and Figure 6F-G showed that miR-17 negatively regulated luciferase activity of the wild-type Keap1 3’UTR luciferase reporter but not that of the mutant reporter. Consistent with the regulation of oxidative stress, inhibition of miR-17 reduced insulin-stimulated pAkt, mGlut4 and glucose uptake in C2C12 myotubes (Figure 6H-K), showing that miR-17 is a positive mediator of insulin signaling. The interaction between miR-17 and miR-200a was also investigated, and Figure 6L showed that miR-17 negatively regulated miR-200a in C2C12 myotubes.

Overexpression of miR-17 also abrogated the decreased glucose uptake in miR-200a-overexpressed C2C12 myotubes in response to insulin (Figure S8E). And inhibition of miR-17-induced miR-200a up-regulation was partly abrogated by SFN and siTxnip (Figure S8F,G). However, miR-17 expression was independent of miR-200a (Figure S8H).

Overexpression of miR-17 in SkM conferred resistance to DEHP-induced oxidative stress and IR

As shown in Figure 6M-O, overexpression of miR-17 in DEHP-exposed C2C12 myotubes revealed parallel downregulation of Keap1, upregulation of Nrf2, and increased GSH/GSSG ratio. Likewise, overexpression of miR-17 increased insulin-stimulated glucose uptake in DEHP-exposed C2C12 myotubes (Figure 6P). SFN failed to reduce miR-200a and oxidative stress and no longer restored glucose uptake in DEHP-exposed C2C12 myotubes when miR-17 was knock down (Figure 6Q-S). In DEHP-exposed mice, the SkM-specific overexpression of
miR-17 using AAV9 (Figure 7A) did not affect body weight and serum insulin (Figure 7B and Figure S9A). No significant difference was observed in serum H$_2$O$_2$ level and GSH/GSSG ratio between DEHP-exposed mice receiving AAV-control and those receiving AAV-miR-17 (Figure 7C-D), suggesting that AAV9-mediated SkM-specific overexpression of miR-17 could not alter DEHP-induced system oxidative stress. However, SkM-specific overexpression of miR-17 resulted in a significant improvement in higher blood glucose (Figure 7E), glucose intolerance (Figure 7F), and insulin insensitivity (Figure 7G,H), and moreover, rescued the SkM from the suppression of insulin-stimulated pAkt and mGlu4 (Figure 7I). AAV-miR-17 also downregulated miR-200a in SkM of DEHP-exposed mice (Figure 7J). For redox homeostasis, exogenous expression of miR-17 reduced GSH/GSSG ratio (Figure 7K) and H$_2$O$_2$ content (Figure 7L), activated Keap1-Nrf2 pathway and decreased Txnip in SkM of DEHP-exposed mice (Figure 7M,N). Additionally, mitochondrial swelling and vacuolization in SkM were not present when DEHP-exposed mice were injected with AAV-miR-17 (Figure 7O).

Dnmt3a and IncRNA Malat1 cooperatively suppressed miR-17 in SkM

Figure 8A-C showed that exposure to DEHP increased the level of the DNA methyltransferases Dnmt3a in SkM of mice. 5-Azacytidine (5-Aza), a synthetic Dnmt inhibitor, decreased Dnmt3a and partly increased miR-17 and insulin-stimulated glucose uptake in DEHP-exposed C2C12 myotubes (Figure 8D-F). Notably, the decrease in miR-17 was not completely corrected by 5-Aza in DEHP-exposed C2C12 myotubes, so an additional mechanism might be involved in regulating miR-17 in SkM under DEHP exposure. LncRNAs function as ceRNAs to sponge miRNAs, and Figure 8G-H showed that DEHP increased the expression of IncRNA Malat1 in SkM cells both in vivo and in vitro. 5-Aza treatment together with IncRNA Malat1 siRNA fully antagonized the decreases in miR-17, GSH/GSSG ratio and insulin-stimulated glucose uptake in DEHP-exposed C2C12 myotubes, and the increases in H$_2$O$_2$ (Figure 8I-O). Unlike miR-17, a decrease of miR-200a expression was showed in DEHP-exposed C2C12 myotube when cotreated with 5-Aza and IncRNA Malat1siRNA and either IncRNA Malat1siRNA (Figure 8P).

Discussion

Exposure to DEHP is a potent contributor to the development of T2D. Our current study indicated that DEHP decreased Insr and Irs1 in SkM of mice. Downregulation of Insr and Irs1 by DEHP led to deactivation of Akt in response to insulin, which subsequently suppressed glucose uptake by decreasing mGlu4 in SkM, ultimately promoting the development of whole-body IR. Although this study set up an DEHP-exposed animal model to study SkM-IR and whole-body glucose homeostasis, we further found that 18-week high-fat diet (40.86% fat, 21.24% protein, and 37.9% carbohydrates, with energy of 4.398 kJ/g) feeding induced similar changes in miR-17, Keap1, Nrf2 and miR-200a expression patterns in SkM in male C57BL/6 mice (Figure S10), compared with the mice model of DEHP-triggered IR. Moreover, regulation and biological function of miR-17 and miR-200a in regulating insulin-stimulated pAkt, mGlu4 and glucose uptake via Keap1-Nrf2 and Irs1/Insr were also demonstrated in C2C12 myotubes. Therefore, we suggested that it would be possible to extend this work to other models of IR. Of course, it should be also noted that more supplementary experiments are still needed to test whether the role of miR-17/Keap1-Nrf2/miR-200a cascade could appropriately work in other animal models of SkM-IR.

In this study, we identified for the first time that both Insr and Irs1 were direct targets of miR-200a that control insulin signaling in C2C12 myotubes and suggested a function of miR-200a in promoting SkM-IR. The miR-200 family has been linked to the disorders of glucose homeostasis as an adverse factor. The miR-200 family was upregulated in pancreatic islets of 12-week-old db/db mice [22]. Moreover, β cell-specific overexpression of miR-200c triggered β cells apoptosis and T2D, and conversely, ablation of miR-200c ameliorated T2D in mice [22]. miR-200a, miR-200b and miR-429 were also reported to be upregulated in the hypothalamus of ob/ob mice, and the hypothalamic silencing of miR-200a increased Irs2 and restored liver insulin responsiveness [23]. However, there were also paradoxical changes in miR-200a coexisting in liver tissues during diabetes [24, 25], which unveiled the possibility that miR-200a was expressed in a tissue-selective manner during metabolic disturbance. In SkM, this study supported the facilitating role of miR-200a in IR by showing that DEHP-decreased glucose uptake resulted from the miR-200a-impaired insulin signaling. Injection of anti-miR-200a lentivirus abrogated the down-regulation of Insr and Irs1 and restored insulin-dependent pAkt and Glu4 translocation in SkM of DEHP-exposed mice, consequently ameliorating whole-body IR. However, we noted that the blood glucose remains unchanged and serum insulin was decreased in DEHP-exposed mice after LV-miR-200a injection. We speculated that this is most probably...
because administration of lentiviruses resulted in transgene expression in several tissues other than SkM. For instance, hepatic miR-200a downregulation would inhibit the activation of the Akt/Gsk pathway and decreased the glycogenesis in the hepatocytes [25]. Under this circumstance, some unpredicted results may be obtained. As a result, accurate determination of miRNA expression patterns in different tissue and cell types is essential to achieve miRNA-based therapy [32]. Improving defects in glucose uptake by SkM-specific correction of miR-200a expression would be a good way to prevent the development of T2D at its earliest stages.

Figure 5. Inhibition of miR-200a improved DEHP-induced IR. DEHP-exposed mice were infected with control lentivirus (LV-Control) or anti-miR-200a lentivirus (LV-miR-200a) (n = 6 mice per group). A. The expression of miR-200a in SkM. U6 was used to normalized miR-200a expression (n = 3 mice per group). B. The body weight (n = 6 mice per group). C. The serum level of H2O2 (n = 6 mice per group). D. The fasting serum insulin (n = 6 per group). E. The IPGTT (n = 5 mice per group). The calculated AUC of the IPGTT were shown in Figure S4B. F. The ITT (n = 5 mice per group). G. The KITT obtained in the ITT (0-30min). H-I. The expression and phosphorylation of Insr and Irs1 in SkM. Quantitative results (I) were normalized by Gapdh (n = 3 mice per group). J. The immunofluorescent detection of Irs1 in SkM (400×, n = 3 mice per group). K. The insulin stimulated pAkt and mGlut4 in SkM. Quantitative results were
normalized by Gapdh and shown in Figure S4C (n = 3 mice per group). L. The H2O2 content normalized to protein content in SkM (n = 3 mice per group). M. The mRNA expression of genes related to oxidative stress. Gapdh was used as the loading control (n = 3 mice per group). All data were presented as the mean ± SEM. *P < 0.05 DEHP-exposed mice infected with LV-Control vs. control mice infected with LV-Control, **P < 0.01 DEHP-exposed mice infected with LV-Control vs. control mice infected with LV-Control. #P < 0.05 DEHP-exposed mice infected with LV-Control vs. DEHP-exposed mice infected with LV-miR-200a.

Figure 6. Downregulation of miR-17 impaired glucose uptake by promoting oxidative stress via targeting keap1. A-D. The representative western blot images (A) and quantification (B-D) of genes related to oxidative stress. Gapdh was used as the loading control. C2C12 myotubes were transfected with 50 nM agomiR-17 or 200 nM antagoniR-17 for 48 h (n = 3 independent experiments). E. The miR-17 target regions in 3'UTR of Keap1. Mmu, mouse; Rno, rat; Hsa, human. WT: a truncated Keap1-3'UTR with wild-type miR-17 binding site; MT: a truncated Keap1-3'UTR with mutated miR-17 binding site. F-G. The relative luciferase activity in C2C12 myoblasts transfected with reporter vector containing the wild-type (F) or mutated (G) Keap1 3'UTR together with agomiR-17, antagoniR-17 or corresponding controls (n = 4 independent experiments). H-J. The representative western blot images (H) and quantification (I-J) of pAkt and mGlut4 in C2C12 myotubes treated with antagomiR-17 (n = 3 independent experiments). Gapdh was used as the loading control. K. The insulin-stimulated 2-DG uptake in C2C12 myotubes treated with antagomiR-17 (n = 3 independent experiments). L. The expression of miR-200a in C2C12 myotubes transfected with agomiR-17 and antagoniR-17 (n = 3 independent experiments). U6 was used to normalized miR-200a expression. M-P. C2C12 myotubes were transfected with 50 nM agomiR-17 and treated with 25 µM DEHP (n = 3 independent experiments).
used as the loading control. **O.** The calculated GSH/GSSG ratio. The levels of GSH and GSSG were shown in Figure S8C-D. **P.** The insulin-stimulated 2-DG uptake. **Q-S.** C2C12 myotubes were co-treated with 25 µM DEHP, antiagomir-17, SFN or corresponding controls (n = 3 independent experiments). **Q.** The expression of miR-200a normalized by U6. **R.** The mRNA expression of Txnip. Gapdh was used as the loading control. **S.** The insulin-stimulated 2-DG uptake. All data were presented as the mean ± SEM. **P** < 0.05, **PP** < 0.01 vs. corresponding control as indicated.

**Figure 7.** Overexpression of miR-17 in SkM was resistant to DEHP-induced oxidative stress and IR. The miR-17 was overexpressed in SkM of DEHP-exposed mice using recombinant adenovirus delivery method (n = 6 mice per group). **A.** The expression of miR-17 in SkM. U6 was used to normalized miR-17 expression (n = 3 mice per group). **B.** The Body weight (n = 4 mice per group). **C.** The serum level of H2O2 (n = 5 mice per group). **D.** The GSH/GSSG ratio calculated by the serum levels of GSH (Figure S9B) and GSSG (Figure S9C) (n = 5 mice per group). **E.** The fasting blood glucose level (n = 6 mice per group). **F.** The IPGTT (n = 5 mice per group). The calculated AUC of the IPGTT were shown in Figure S9D. **G.** The ITT (n = 5 mice per group). **H.** The KITT obtained in the ITT (0-30min). **I.** The representative western blot images of pAkt and mGlut4 in SkM (n = 3 mice per group). Gapdh was used as the loading control and the quantification data were shown in Figure S9E-F. **J.** The expression of miR-200a in SkM. U6 was used to normalized miR-200a expression (n = 3 mice per group). **K.** The GSH/GSSG ratio in SkM (n = 3 mice per group). Levels of GSH and GSSG were shown in Figure S9G-H, respectively. **L.** The H2O2 content in SkM (n = 3 mice per group). **M.** The representative western blot images of genes related to oxidative stress (n = 3 mice per group). The total protein was normalized by Gapdh and the protein expression of Nrf2 in nuclear were normalized by Lamin B1. The quantification data were shown in Figure S9I. **N.** The representative images of immunohistochemical staining of genes related to oxidative stress. (Scale bar = 50 µm). **O.** The representaitve TEM images of SkM (Scale bar =
200nm, n = 3 mice per group). Mitochondria were indicated by black arrowheads. Calculation of mitochondrial area was shown in the Figure S9J. All data were presented as the mean ± SEM. *P < 0.05 control mice infected with AAV-Control vs. DEHP-exposed mice infected with AAV-Control, **P < 0.01 control mice infected with AAV-Control vs. DEHP-exposed mice infected with AAV-Control, ***P < 0.05 DEHP-exposed mice infected with AAV-Control vs. DEHP-exposed mice infected with AAV-miR-17, ****P < 0.01 DEHP-exposed mice infected with AAV-Control vs. DEHP-exposed mice infected with AAV-miR-17.

Figure 8. Dnmt3a and IncRNA Malat1 cooperatively suppressed miR-17 in SkM. A-C. The mRNA (A) and protein (B-C) levels of DNA methyltransferase in SkM of DEHP-exposed mice (n = 4 mice per group qRT-PCR analysis and n = 3 mice per group for western blot). Gapdh was used as the loading control. D. The mRNA expression of Dnmt3a in DEHP-exposed C2C12 myotubes co-treated with 5-Aza (n = 3 independent experiments). Gapdh was used as the loading control. E. The expression of miR-17 in DEHP-exposed C2C12 myotubes co-treated with 5-Aza (n = 3 independent experiments). U6 was used to normalized miR-17 expression. F. The insulin-stimulated 2-DG uptake

http://www.thno.org
In this study, no evidence of relationship between the dose of DEHP and the expression of miR-200a, Insr and Irs1 in C2C12 myotubes was observed. Presently, we could only offer some speculation. Firstly, the hazard and risk assessment of chemicals with endocrine activity is hotly debated partly due to non-monotonous dose-response, and there were evidence suggesting that EDCs have non-linear dose-response effects [33, 34]. The dose-response relationships between urinary phthalate metabolites and thyroid hormone parameters were reported to be non-monotonic among the waste plastic recycling workers [35]. And there were also studies indicating non-linear associations of phthalate metabolites (ΣDEHP) with IR indices [36]. Metabolic reactions could be partly responsible for the non-linear dose-response relationships of DEHP [37]. DEHP absorbed in the body is metabolized into MEHP and in vitro cultured cells also have the capacity to convert of DEHP to its metabolites [38]. Enzymes involved in DEHP metabolism might display non-linear concentration-velocity relationships with respect to substrates or co-factors, resulting in different efficiency of metabolic activation and detoxification of DEHP. In addition, higher-dose exposure would also affect other regulatory pathways, and the response to these pathway and factors might also counteract or interfere with the stimulation produced by DEHP at miR-200a, Insr and Irs1 expression. Finally, a limitation of this in vitro experimental design was the relatively narrow-range exposure dose. It seemed not to be suitable for dose-response analyses. Experiments varied the exposure doses over a wider range are need for further dose-response study of DEHP.

In this study, a reduction/oxidation imbalance was shown in SkM of DEHP-exposed mice. The cross-talk between the miR-200 family and redox homeostasis modulation has been studied, and H2O2 was reported to upregulate miR-200 family in HUVECs, C2C12 myoblasts [19, 39] and liver cells [21]. Upregulation of the miR-200 family, especially miR-200c, in turn, further enhanced oxidative stress. Oxidative stress plays a central role in the pathogenesis of IR and diabetes, which promotes the use of antioxidants as a complementary therapeutic approach. In this study, the onset of hyperglycemia and IR was indeed alleviated in DEHP-exposed mice after NAC treatment, which was parallel to the decreases in miR-200a. However, it was interesting, that anti-miR-200a lentivirus did not alleviate DEHP-increased H2O2 in the SkM. miR-200a might be a target or downstream mediator of redox imbalance in SkM during IR.

Keap1-Nrf2 signaling is a key antioxidant system that can detoxify exogenous toxicants to maintain cellular homeostasis [17, 40, 41]. Decreased Nrf2 rendered cells susceptible to oxidative stress. Previously, we found that DEHP deactivated the Nrf2-mediated antioxidant response in INS-1 cells, resulting in insulin-secretion deficiency [8]. Similarly, Nrf2 was downregulated by DEHP in SkM, associated with increased Keap1. The relationship between miR-200 family and Keap1-Nrf2 signaling is a matter of great concern, and there were some studies showing that miR-200a regulated Nrf2 activation by targeting Keap1 [42-44]. Actually, in our previous study, we also reported that miR-200a and miR-141 acted to target Keap1 in renal mesangial cells, resulting in profound dysregulations in Keap1-Nrf2 signaling during the development of diabetic nephropathy. However, this current study unexpectedly found that miR-200a did not regulate Keap1-Nrf2 signaling in SkM and C2C12 myotubes (Figure S5). Instead, the expression of miR-200a, along with the impaired glucose disposal and insulin signaling, was reversed by SFN treatment in DEHP-exposed C2C12 myotubes. This finding was in agreement with studies reporting that oxidative stress has an effect to upregulate miR-200 family in several cell types [19, 21, 39, 45]. We believed that miR-200a acted as an oxidative stress-responsive factor, and the Keap1-Nrf2 antioxidant system played a critical role in maintaining insulin sensitivity in SkM.

Nrf2 is also a key gatekeeper of Txnip transcription, which maintains the low-level basal expression of Txnip [46]. Nrf2 alleviated the oxidative damage of cardiomyocytes in diabetic mice by repressing Txnip [46]. The absence of Txnip led to excess glucose uptake in muscle, causing hyperglycemia [47]. Downregulation of TXNIP in muscle via caloric restriction [48] or exercise training [49] improved insulin signaling and peripheral glucose metabolism in humans. In accordance, DEHP-induced oxidative stress that contributed to increased Txnip in SkM, which was mechanistically associated with diminished activity of insulin-dependent Akt and glucose transport. Txnip potentially played a role in
the regulation of several miRNAs including miR-204 [50], miR-124a [51] and miR-200 [52], that mediated the Txnip-induced inhibition of insulin production and sensitivity under diabetic conditions. With regard to miR-200a, Txnip elevated its expression in pancreatic β cells and thereby promoted β cells apoptosis [52] and this study further identified the direct transcriptional regulatory action of Txnip on miR-200a in SkM.

Apart from miR-200a, DEHP decreased miR-17 in SkM. miR-17 is one of key players in the pathogenesis of T2D [53-57]. Serum miR-17 was consistently reported to be downregulated in patients with T2D [58-61]. In diabetic mice, expression of miR-17 was also lower in macrophages than normal mice, and upregulation of miR-17 indirectly increased insulin-stimulated glucose uptake by preventing inflammatory cytokine secretion, therefore significantly improved inflammation-induced IR [56]. Pancreatic β-cell dysfunction and IR are two major causes for T2D. Conditional deletion of miR-17 in mouse pancreatic β cells significantly reduced glucose tolerance and glucose-stimulated insulin secretion [55], finally promoting the development of experimental diabetes. Insulin-resistant subjects also exhibit decreased insulin sensitivity in major insulin target tissues including liver, adipose tissue and skeletal muscle, and there were studies demonstrating that miR-17-92 cluster was involved in insulin signal transduction in these organs. In obese mice, lower expression of miR-17 was detected in omentum fat, which interacted with genes including GLUT4 and so on to regulate insulin sensitivity in adipose tissue and increased fasting blood glucose and glycosylated hemoglobin [53]. In a rat model of streptozotocin and high-fat diet-induced T2D, miR-17 family, especially miR-17, was also downregulated in the hepatocytes. Moreover, miR-17 overexpression enhanced insulin sensitivity in HepG2 and LO2 cells, characterized by altered phosphorylation on Insr signaling pathway proteins [62]. However, there was a study reporting that miR-17 impaired glucose metabolism by repressing Glut4 in SkM of a high-fat diet STZ-induced rat model and palmitic acid-exposed L6 rat skeletal muscle cell line [63]. Our current study supported the antidiabetic role of miR-17, because DEHP-induced glucose intolerance, Akt inactivation, and mGlut4 attenuation were abolished when miR-17 was overexpressed in SkM by AAV-miR-17. Although the expression of Glut4 in antagomiR-17-treated total cell lysates was unaltered following insulin treatment, decreased plasma membrane concentration of Glut4 and the parallel impairment of glucose uptake were shown in C2C12 myotubes under these conditions. Whether the influence of miR-17 on the expression of target genes involved in insulin signal and glucose uptake might differ according to the species and cell types, is at present unclear and remains to be demonstrated in future studies. But importantly, our study further revealed a novel function of miR-17 in physically interacting with Keap1 and Txnip in SkM. Overexpression of miR-17 in C2C12 myotubes inhibited keap1 and Txnip and downregulated miR-200a, which corresponded with the improved pAkt and glucose uptake. Highly conserved seed sequences for miR-17 in the Txnip 3′UTR were previously reported, and Txnip was predictably modulated by miR-17 in INS-1 cells [57]. This study discovered that the 3′UTR of Keap1 contained a conserved binding site that matched miR-17 in humans, mice and rats and first identified the direct regulation of Keap1 by miR-17 in C2C12 myotubes. Above all, it was believed that the alteration of Glut4 in either miR-17-knockdown or DEHP-exposed SkM cells was most likely a consequence rather than a cause of SkM-IR. Inhibition of miR-17 upregulated miR-200a to impair Glut4 translocation and muscle-specific glucose uptake in response to insulin signaling by inducing oxidative stress in SkM through direct targeting Keap1 and Txnip, ultimately controlling over whole-body glucose homeostasis. miR-17 acted as an activator, whereas miR-200a acted as an inhibitor that regulated insulin action and glucose homeostasis.

Interestingly, this study found that SFN failed to reduce miR-200a and oxidative stress, and to restore glucose uptake in DEHP-exposed C2C12 myotubes when miR-17 was knockdown, suggesting that antioxidant effects of miR-17 was stronger than those of the small molecule Nrf2 inducer SFN. SFN is an electrophilic entity with very small molecular weight and poor aqueous, and this activator has some additional disadvantages hindering its development as a drug, such as the relatively low potency in functional assays measuring the induction of antioxidant proteins and the activation of ROS-detraining enzymes [64]. Precision therapeutics to target dysregulated miRNA can be an appropriate target for disease treatment. Some miRNA-based therapies have been entering into the earlier-phase clinical trials [32, 65]. As just one example, antimiR against miR-122, miravirsen (Santaris Pharma), has been currently in a Phase II clinical trial (Clinical Trial Number: NCT01200420) to treat hepatitis C virus (HCV) patients [66]. Therefore, targeting the regulation of the Nrf2 signaling pathway by miR-17 would potentially lead to the development of innovative therapeutic strategies for oxidative stress-induced complications, particularly SkM-IR. On the other hand, intramuscular injection of AAV9-delivered miR-17 resulted in the protection of SkM
against oxidative stress and IR, but DEHP-induced changes in serum oxidative stress parameters (H₂O₂, GSH and GSSG) were not ameliorated. Indeed, due to the functional complexity, the same miRNA may differ in expression and its targets among different tissues and cell types from the same disease [32]. Designing an optimal miR-17 delivery strategy that maintains sufficient molecular stability and enables SkM-specific targeting is particularly important to enable miR-17-based therapeutics in IR and T2D to become a reality.

In this study, exposure to DEHP increased Dnmt3a in SkM of mice. Dnmt3a is a methyltransferase that is responsible for the de novo methylation of promoter CpGs with different targets. The expression of miRNA can be regulated by Dnmt3a-dependent promoter methylation [67, 68]. In NIH 3T3 fibroblasts, Dnmt3a induced methylation of the miR-17 promoter to decrease its expression [68]. Similarly, cotreatment of DEHP-exposed C2C12 myotubes with 5-Aza-induced downregulation of Dnmt3a partly restored miR-17 expression and the subsequent decreases in glucose uptake. Thus, it was reasonable to postulate that the DEHP-induced downregulation of miR-17 might be partially attributed to the Dnmt3a-triggered promoter methylation of miR-17. In addition to epigenetic regulation by methylation, lncRNA Malat1 was shown to function as a competitive endogenous RNA to sponge miR-17. Higher level of lncRNA MALAT1 and lower level of miR-17 were detected simultaneously in patients with diabetes who smoked [69]. Knockdown of lncRNA MALAT1 induced an increase in miR-17, which then suppressed TXNIP and promoted the production of insulin in pancreatic β cells [69]. In this study, complete recovery of miR-17 and normalized GSH and insulin-stimulated glucose uptake were exhibited in DEHP-exposed C2C12 myotubes after combined treatment with lncRNA Malat1 siRNAs and 5-Aza. Dnmt3a and lncRNA Malat1 cooperatively suppressed miR-17, thereby regulating downstream factors of the Txnip and keap1-Nrf2 pathways related to the oxidative stress and IR. More in vivo investigations are required for further exploration. In fact, apart from miR-17, the promoter methylation of miRNA and the sponge role of lncRNA for several miRNAs have been reported. For miR-200a, it was reported that miR-200a-5p [70] and miR-200a [71] could be methylated by Dnmt3a in the process of breast cancer proliferation. Besides, there were studies also reporting that lncRNA Malat1 participated in proliferation, migration, and invasion in human hepatoma Hep3B [72] and non-small cell lung cancer cells [73] via sponging miR-200a. But notably, IR and cancer are totally different pathological and physiological conditions. In this study, miR-200a was decreased after that lncRNA Malat1 and Dnmt3a was inhibited in DEHP-exposed C2C12 myotube. As a result, we suggested that either Dnmt3a or lncRNA Malat1 indirectly regulated miR-200a in insulin-resistant SkM, which should be independent of methylation-associated silence and miRNA sponges, respectively.

In summary, this study identified a novel pathway by which DEHP decreased miR-17 to induce oxidative stress through Keap1-Nrf2 and Txnip. The Dnmt3a-dependent methylation of promoter and lncRNA Malat1-related sponge functions jointly regulated miR-17. In SkM, the induction of oxidative stress upregulated miR-200a which served to inhibit Insr and Irs1, thus decreasing the insulin-mediated activation of Akt and glucose uptake and ultimately resulting in IR (Figure 8Q). The signaling node of miR-17/Keap1-Nrf2/miR-200a is a good treatment and prevention option for IR and T2D.

Abbreviations

2-DG: 2-deoxyglucose; 3′UTR: 3′untranslated regions; AAV9: adeno-associated virus 9; DEHP: di(2-ethylhexyl) phthalate; DMEM: dulbecco’s modified Eagle medium; EDCs: environmental endocrine-disrupting chemicals; FBS: fetal bovine serum; GSH: glutathione; IR: insulin resistance; Insr: insulin receptor; Irs1: insulin receptor substrate 1; Keap1: kelch like ECH associated protein 1; NAC: N-acetylcysteine; Nrf2: nuclear factor (erythroid-derived 2)-like 2; miRNA: microRNA; GSSG: oxidized glutathione; Akt: serine/threonine kinase; SFN: sulforaphane; SkM: skeletal muscle; Glut4: solute carrier family 2 member 4; TEM: transmission electron microscope; T2D: Type 2 diabetes.

Supplementary Material

Supplementary figures and tables. http://www.thno.org/v10p9230s1.pdf

Acknowledgements

The work was supported by the National Natural Science Foundation of China [21677140 and 81502782]; the Fundamental Research Funds for the Central Universities [20720190081]; the Scientific Research Support Program for Young Teachers of School of Medicine, Xiamen University; and the Open Research Fund of State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics [SKLVD2020KF03].

Author Contributions

J.Wei and Y.Lin designed the study, analyzed the data and wrote the manuscript. J.Wei, Q.Hao,
C. Cheng, X. Han, T. Wang, H. Li, Y. Ding, W. Huang, Y. Hu, S. Lin, and Y. Lin contributed to research data. X. You and X. Chen help to carry out additional experiments in the revision of manuscript. J. Wei, J. Li, and Y. Wang carried out biochemical analysis. Z. Lei edited the manuscript. H. Shen reviewed the manuscript and part of experiments was performed in H. Shen's lab. J. Wei and Y. Lin are guarantors of this work and as such, have full access to all data and take responsibility for the accuracy of the data.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Lind PM, Lind L. Endocrine-disrupting chemicals and risk of diabetes: an evidence-based review. Diabetologia. 2018; 61: 1495-502.
2. Dales RE, Kauri LM, Cakmak S. The associations between phthalate exposure and insulin resistance, beta-cell function and blood glucose control in a population-based sample. Sci Total Environ. 2018; 612: 1287-92.
3. Attina TM, Trasande L. Association of Exposure to Di-2-Ethylhexylphthalate (DEHP) With Increased Insulin Resistance in Adolescents From NHANES 2009-2012. J Endocr Metab. 2015; 107: 1021-30.
4. Trasande L, Spanier AJ, Sathyanarayana S, Attina TM, Blustein J. Urinary phthalates and increased insulin resistance in adolescents. Pediatrics. 2013; 132: e56-64.
5. Stahlhut RW, van Wijngaarden E, Dye TD, Cook S, Swan SH. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. Environ Health Perspect. 2007; 115: 676-82.
6. James-Todd T, Stahlhut R, Tripathy D, Cakmak S. The associations between phthalate exposure and insulin resistance, beta-cell function and blood glucose control in a population-based sample. Sci Total Environ. 2018; 612: 1287-92.

http://www.thno.org
46. He X, Ma Q. Redox regulation by nuclear factor erythroid 2-related factor 2: gatekeeping for the basal and diabetes-induced expression of thioredoxin-interacting protein. Mol Pharmacol. 2012; 82: 887-97.
47. Waldherr AN, Dykstra H, Peck AS, Boguslawski EA, Madaj ZB, Wen J, et al. Phosphorylation of TXNIP by AKT mediates acute influx of glucose in response to insulin. Cell Rep. 2017; 19: 2005-13.
48. Johnson ML, Distelmaier K, Lanza IR, Irving BA, Robinson MM, Konopka AR, et al. Mechanism by which caloric restriction improves insulin sensitivity in sedentary obese adult mice. Diabetes. 2016; 65: 74-84.
49. Gorgens SW, Benninghoff T, Eckardt K, Springer C, Chadt A, Melior A, et al. Hypoxia in combination with muscle contraction improves insulin action and glucose metabolism in human skeletal muscle via the HIF-1alpha pathway. Diabetes. 2017; 66: 2800-7.
50. Xu G, Chen J, Jing G, Shalev A. Thioredoxin-interacting protein regulates insulin transcription through miRNA-204. Nat Med. 2013; 19: 1141-6.
51. Jing G, Westwell-Roper C, Chen J, Xu G, Verchere CB, Shalev A. Thioredoxin-interacting protein promotes islet amyloid polypeptide expression through miR-124a and FoxA2. J Biol Chem. 2014; 289: 11807-15.
52. Filios SR, Xu G, Chen J, Hong K, Jing G, Shalev A. MicroRNA-200 is induced by thioredoxin-interacting protein and regulates Zeb1 protein signaling and beta cell apoptosis. J Biol Chem. 2018; 293: 36275-83.
53. Heneghan HM, Miller N, McAnena OJ, O’Brien T, Kerin MJ. Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. J Clin Endocrinol Metab. 2011; 96: E846-50.
54. Thomaidsou S, Kracht MJL, van der Silik A, Laban S, de Koning EJ, Laban S, et al. Beta-Cell Stress Shapes Critical Recognition of Preproinsulin Signal Peptide by Post-Transcriptional Regulation of Endoplasmic Reticulum Aminopeptidase I. Diabetes. 2020; 69: 670-80.
55. Chen Y, Tian L, Wan S, Xie Y, Chen X, Ji X, et al. MicroRNA-17-92 cluster regulates pancreatic beta-cell proliferation and adaptation. Mol Cell Endocrinol. 2016; 437: 213-23.
56. Zhang C, Qian D, Zhao H, Lv N, Yu P, Sun Z. MiR17 improves insulin sensitivity through inhibiting expression of ASK1 and anti-inflammation of macrophages. Biomed Pharmacother. 2018; 100: 448-54.
57. Lerner AG, Upton JP, Praveen PV, Gosh R, Nakagawa Y, Igbabia A, et al. IRE1alpha induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irreparable ER stress. Cell Metab. 2012; 16: 250-64.
58. Karolina DS, Tavintharan S, Armugam A, Sepramaniam S, Pek SL, Wong MT, et al. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab. 2012; 97: E2271-6.
59. Liu K, Sewe M, Yong W. A Pilot Study: The Effect of Roux-en-Y Gastric Bypass on the Serum MicroRNAs of the Type 2 Diabetes Patient. Obes Surg. 2015; 25: 2386-92.
60. He Y, Ding Y, Liang R, Lin J, Kim TK, Yu H, et al. A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus. Int J Mol Sci. 2017; 18: 456.
61. Deiuliis JA. MicroRNAs as regulators of metabolic disease: pathophysiological significance and emerging role as biomarkers and therapeutics. Int J Obes (Lond). 2016; 40: 88-101.
62. Ye D, Lou G, Zhang T, Dong F, Liu Y. MiR-17 family-mediated regulation of Pkmov1 influences hepatic steatosis and insulin signaling. J Cell Mol Med. 2018; 22: 6167-75.
63. Xiao D, Zhou T, Fu Y, Wang R, Zhang H, Li M, et al. MicroRNA-17 impairs glucose metabolism in insulin-resistant skeletal muscle via repressing glucose transporter 4 expression. Eur J Pharmacol. 2018; 836: 170-6.
64. Boehm J, Davis R, Murar CE, Li T, McCleland B, Dong S, et al. Discovery of a crystalline sulforaphane analog with good solid-state stability and engagement of the Nrf2 pathway in vitro and in vivo. Bioorg Med Chem. 2019; 27: 579-88.
65. Ni J, Bucci J, Chang L, Malouf D, Graham P, Li Y. Targeting MicroRNAs in Prostate Cancer Radiotherapy. Theranostics. 2017; 7: 3243-59.
66. Janssen HL, Riesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013; 368: 1685-94.
67. Kim BG, Gao MQ, Kang S, Choi YP, Lee JH, Kim JE, et al. Mechanical compression induces VEGFA overexpression in breast cancer via DNM3TA-dependent miR-9 downregulation. Cell Death Dis. 2017; 8: e2846.
68. Yang ZG, Awan FM, Du WW, Zeng Y, Lyu J, et al. The Circular RNA Interacts with STAT3, Increasing Its Nuclear Translocation and Wound Repair by Modulating Dnmt3a and miR-17 Function. Mol Ther. 2017; 25: 2062-74.
69. Sun Q, Xu H, Xue J, Yang Q, Chen C, Yang P, et al. MALAT1 via microRNA-17 regulation of insulin transcription is involved in the dysfunction of pancreatic beta-cells induced by cigarette smoke extract. J Cell Physiol. 2018; 233: 8862-73.
70. Zeng X, Qu X, Zhao C, Xu L, Hou K, Liu Y, et al. FEN1 mediates miR-200a methylation and promotes breast cancer cell growth via MET and EGFR signaling. FASEB J. 2019; 33: 10717-30.
71. Yu Y, Wu J, Guan L, Qi L, Tang Y, Ma B, et al. Kindlin-2 promotes breast cancer invasion via epigenetic silencing of the miRNA200 gene family. Int J Cancer. 2013; 133: 1368-79.
72. Zhao ZB, Chen F, Bai XF, Long. Noncoding RNA MALAT1 Regulates Hepatocellular Carcinoma Growth Under Hypoxia via Splicing MicroRNA-200a. Yonsei Med J. 2019; 60: 727-34.